AdvaMed Announces 200 Million Molecular COVID-19 Tests Shipped Nationwide

WASHINGTON, D.C. – New data from AdvaMed’s COVID-19 Diagnostic Supply Registry reveals that total U.S. shipments of COVID-19 molecular diagnostic tests have reached 200 million. A breakdown of the data shows that innovative diagnostics companies are shipping, on average, over 1.4 million molecular tests each day.

“For the past few months, our diagnostics companies have made it clear they’ll do whatever it takes to stay ahead of COVID-19 testing demand to help bring this pandemic under control,” said Scott Whitaker, president and CEO of AdvaMed. “200 million molecular tests shipped nationwide since the beginning of the pandemic is a remarkable testament to their commitment to saving lives.”

According to the Registry, approximately 121 million COVID-19 molecular tests have been administered as of October 10.

Unveiled July 21, AdvaMed’s Registry compiles information from leading diagnostics companies along with publicly available data on daily tests performed to create a centralized and standardized COVID-19 diagnostic supply registry. The registry provides weekly state- and national-level updates on the number of molecular, and serology (antibody) tests shipped in the U.S. to help state and federal governments in their pandemic responses. AdvaMed and AdvaMedDx, the association’s division of diagnostics companies, developed the National Testing Registry in partnership with 13 commercial diagnostics manufacturers: Abbott, BD, bioMérieux, Bio-Rad, Beckman Coulter, Cepheid, Hologic, Ortho Clinical Diagnostics, QIAGEN, Roche Diagnostics, Sekisui Diagnostics, Siemens Healthineers, and Thermo Fisher Scientific. 

# # #

AdvaMed member companies produce the medical devices, diagnostic products and health information systems that are transforming health care through earlier disease detection, less invasive procedures and more effective treatments. AdvaMed members range from the largest to the smallest medical technology innovators and companies. For more information, visit www.advamed.org.